Related Experiment Videos
The crystal structure of human cathepsin L complexed with E-64
A Fujishima1, Y Imai, T Nomura
1Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Yodogawa-ku, Osaka, Japan. fujishim@lab.takeda.co.jp
FEBS Letters
|April 21, 1997
Summary
We determined the 3D structure of human cathepsin L bound to E-64, revealing key differences in its active site compared to cathepsin B. This structural insight aids in designing targeted cysteine protease inhibitors.
Area of Science:
- Biochemistry
- Structural Biology
- Enzymology
Background:
- Cysteine proteases, like human cathepsin L, are crucial enzymes involved in various physiological and pathological processes.
- Understanding the active site architecture is essential for developing specific enzyme inhibitors.
- Cathepsin L plays a role in protein degradation and is implicated in diseases such as cancer and arthritis.
Purpose of the Study:
- To elucidate the three-dimensional structure of the human cathepsin L-E-64 complex.
- To compare the active site features of human cathepsin L with those of cathepsin B.
- To provide structural insights for the rational design of novel cathepsin L inhibitors.
Main Methods:
- X-ray crystallography was employed to determine the structure of the human cathepsin L-E-64 complex.
- The structure was resolved at 2.5 Angstrom resolution.
- Comparative analysis of active site residues and pockets between cathepsin L and cathepsin B was performed.
Main Results:
- The three-dimensional structure of human cathepsin L in complex with E-64 was determined at 2.5 A resolution.
- Significant differences were observed in the S' subsites due to an 'occluding loop' in cathepsin B.
- The S2 pocket of cathepsin L was found to be shallow and narrow, contrasting with cathepsin B.
- The S3 subsites showed similarity, with cathepsin L potentially accommodating larger groups.
Conclusions:
- The determined structure provides a detailed view of the human cathepsin L active site.
- Structural differences between cathepsin L and B highlight opportunities for selective inhibitor design.
- This knowledge is valuable for developing targeted therapeutics for diseases involving cathepsin L activity.